Aspirin for hepatocellular carcinoma prevention in MASLD: How far are we ready to proceed?: Editorial on “Aspirin and HCC risk in MASLD: Nationwide cohort study with genetic risk analysis”
Abstract
Keywords : aspirin, hepatocellular carcinoma (HCC), metabolic dysfunction-associated steatotic liver disease (MASLD), prevention Aspirin has a long history, originating from its use as an analgesic and antipyretic in ancient civilizations
Fields of Study & Subjects
Hepatocellular Carcinoma Treatment and Prognosis
Liver Disease Diagnosis and Treatment
Cholangiocarcinoma and Gallbladder Cancer Studies
Publication details
- Journal / source
- Clinical and Molecular Hepatology
- Volume
- 32
- Issue
- 3
- Pages
- 1429–1432
- Publication date
- 9 January 2026
- Language
- EN